Medical School · Year 2 · Pharmacology · includes a quiz and discussion video

Lecture 05: CNS Pharmacology

Unit 2.12: Pharmacology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe sedative-hypnotic and anxiolytic drugs
2. Explain antidepressant mechanisms and classes
3. Describe antipsychotic drugs
4. Explain drugs for neurodegenerative diseases
5. Describe antiepileptic drug mechanisms
6. Explain opioid pharmacology and analgesics

Lecture Outline

I. Sedative-Hypnotics

Benzodiazepines constitute one of the most widely prescribed drug classes for anxiety disorders, insomnia, seizures, and procedural sedation, representing a significant advancement over the more dangerous barbiturates they largely replaced. These drugs share a characteristic chemical structure with a benzene ring fused to a diazepine ring and produce their effects through modulation of the GABA-A receptor, the major inhibitory neurotransmitter receptor in the central nervous system. Individual benzodiazepines differ primarily in their pharmacokinetic properties, particularly duration of action, which guides selection for specific clinical indications. Understanding these differences enables rational drug selection while appreciating the class-wide risks of tolerance, dependence, and withdrawal that accompany benzodiazepine use.

Available benzodiazepines span a range of durations of action that influence their clinical applications. Diazepam has a long duration of action due to active metabolites with extended half-lives, making it useful for anxiety disorders, seizures, alcohol withdrawal, and muscle spasticity but unsuitable for insomnia due to residual daytime sedation. Lorazepam has intermediate duration and is available in both oral and parenteral forms, serving as first-line treatment for status epilepticus and acute anxiety. Midazolam is short-acting with rapid onset and is the preferred benzodiazepine for procedural sedation due to its water solubility and predictable offset. Alprazolam has intermediate duration and is widely used for generalized anxiety disorder and panic disorder. Temazepam and triazolam are marketed specifically for insomnia, with triazolam's shorter duration reducing morning sedation but increasing the risk of rebound insomnia and amnesia.

The mechanism of benzodiazepine action involves allosteric modulation of the GABA-A receptor, a ligand-gated chloride channel that mediates fast inhibitory neurotransmission throughout the brain. Benzodiazepines bind to a specific site on the GABA-A receptor distinct from the GABA binding site, and this binding increases the frequency of chloride channel opening in response to GABA. Importantly, benzodiazepines have no effect in the absence of GABA; they potentiate the endogenous neurotransmitter rather than directly activating the receptor. This mechanism explains the relative safety of benzodiazepines compared to barbiturates, as there is a ceiling effect on CNS depression without the ability to directly open chloride channels. The allosteric potentiation produces enhanced inhibitory neurotransmission, resulting in the characteristic anxiolytic, sedative, muscle relaxant, anticonvulsant, and amnestic effects of the benzodiazepine class.

Flumazenil is a competitive benzodiazepine antagonist used to reverse benzodiazepine-induced sedation and respiratory depression in specific clinical scenarios. The drug binds to the same allosteric site on the GABA-A receptor as benzodiazepines but has no intrinsic activity, competitively displacing benzodiazepines and reversing their effects. Clinical uses include reversal of benzodiazepine sedation following procedures and management of benzodiazepine overdose in appropriate patients. A critical concern is that flumazenil can precipitate seizures in patients who are benzodiazepine-dependent (due to lowering of seizure threshold) and in patients who have co-ingested seizure-threshold-lowering drugs such as tricyclic antidepressants. The half-life of flumazenil (approximately 1 hour) is shorter than most benzodiazepines, necessitating repeat dosing or continuous infusion to prevent re-sedation after initial reversal. Flumazenil is contraindicated in patients with known or suspected benzodiazepine dependence and in those with concurrent tricyclic antidepressant or cocaine ingestion.

<image>Panel A: GABA-A receptor structure showing pentameric arrangement with GABA binding site between alpha and beta subunits, benzodiazepine binding site between alpha and gamma subunits, and central chloride channel pore with chloride ion flow producing hyperpolarization. Panel B: Benzodiazepine comparison chart showing diazepam (long-acting, anxiety, seizures), lorazepam (intermediate, status epilepticus), midazolam (short, procedural sedation), alprazolam (intermediate, panic), temazepam (intermediate, insomnia), and triazolam (short, insomnia) with half-lives and clinical uses. Panel C: Benzodiazepine mechanism showing increased chloride channel opening frequency in presence of GABA (not direct opening), ceiling effect limiting CNS depression, and no effect without GABA explaining safety compared to barbiturates. Panel D: Flumazenil reversal diagram showing competitive displacement of benzodiazepine from receptor, reversal of sedation, seizure risk warning in dependent patients, and short half-life requiring monitoring for re-sedation.</image>

II. Other Sedative-Hypnotics

Non-benzodiazepine hypnotics, colloquially known as "Z-drugs," were developed to provide the sleep-promoting effects of benzodiazepines with theoretically reduced potential for tolerance, dependence, and residual sedation. These drugs share the benzodiazepine mechanism of GABA-A receptor potentiation but demonstrate selectivity for receptor subtypes containing the alpha-1 subunit, which mediates sedation, rather than alpha-2 and alpha-3 subunits associated with anxiolytic and muscle relaxant effects. Zolpidem is the most widely prescribed Z-drug, indicated for short-term treatment of insomnia and available in immediate-release, extended-release, and sublingual formulations for different sleep disturbance patterns. Zaleplon has the shortest duration of action among Z-drugs, useful specifically for sleep-onset insomnia and middle-of-the-night awakenings with enough remaining sleep time. Eszopiclone has a longer duration allowing treatment of both sleep-onset and sleep-maintenance insomnia. Despite initial optimism about reduced abuse potential, Z-drugs carry similar risks of dependence, complex sleep behaviors (sleepwalking, sleep-driving), and next-morning impairment, particularly in elderly patients and those taking extended-release formulations.

Barbiturates were the dominant sedative-hypnotics before benzodiazepines but have been largely relegated to specific niche uses due to their significant toxicity and dependence potential. These drugs bind to a different site on the GABA-A receptor than benzodiazepines and produce a distinct effect: increasing the duration of chloride channel opening rather than the frequency. Critically, at higher concentrations, barbiturates can directly open the chloride channel independent of GABA, removing the ceiling effect and enabling potentially lethal respiratory depression in overdose. Phenobarbital remains used as an anticonvulsant, particularly for neonatal seizures and in resource-limited settings. Pentobarbital is used for refractory status epilepticus requiring medically-induced coma and as a veterinary euthanasia agent. Thiopental was historically used for induction of anesthesia but has been largely replaced by propofol. Barbiturate withdrawal, like benzodiazepine withdrawal, can be life-threatening and requires medically supervised tapering.

Several non-GABAergic agents provide alternatives for insomnia and anxiety with different mechanisms and safety profiles. Ramelteon is a melatonin receptor agonist (MT1 and MT2 subtypes) that promotes sleep without GABA-A effects, approved for sleep-onset insomnia with no abuse potential and no dependence; its limitation is modest efficacy compared to benzodiazepines and Z-drugs. Suvorexant and lemborexant are orexin receptor antagonists that block the wake-promoting orexin (hypocretin) system, offering a novel mechanism for insomnia treatment with reported reductions in sleep latency and improvements in sleep maintenance. Buspirone is a serotonin 5-HT1A partial agonist used for generalized anxiety disorder, distinguished from benzodiazepines by its slow onset (2-4 weeks for efficacy), lack of sedative and muscle relaxant effects, no potential for abuse, and absence of cross-tolerance with benzodiazepines or alcohol. Gabapentin and pregabalin bind to alpha-2-delta subunits of voltage-gated calcium channels, reducing excitatory neurotransmitter release; while primarily anticonvulsants, they are used off-label for anxiety and have approved indications for neuropathic pain.

Alcohol (ethanol) is the most widely used sedative-hypnotic worldwide and shares pharmacological properties with benzodiazepines and barbiturates that have important clinical implications. Acute alcohol intoxication results from enhancement of GABA-A receptor function and inhibition of NMDA glutamate receptors, producing the characteristic sedation, disinhibition, and impaired coordination. Chronic alcohol use produces neuroadaptive changes including GABA-A receptor downregulation and NMDA receptor upregulation. Upon abrupt cessation in dependent individuals, the resulting imbalance between reduced inhibition and enhanced excitation produces alcohol withdrawal syndrome, manifesting as autonomic hyperactivity, tremors, anxiety, seizures, and potentially life-threatening delirium tremens. Treatment of alcohol withdrawal utilizes benzodiazepines (chlordiazepoxide, lorazepam, diazepam), which provide cross-tolerance at the GABA-A receptor. Medications for alcohol use disorder include disulfiram, which inhibits aldehyde dehydrogenase causing aversive effects when alcohol is consumed; naltrexone, an opioid antagonist that reduces the rewarding effects of alcohol; and acamprosate, which modulates glutamate transmission to reduce craving.

<image>Panel A: Z-drug mechanism showing selective binding to alpha-1-containing GABA-A receptors producing sedation without anxiolytic or muscle relaxant effects, with comparison of zolpidem (insomnia), zaleplon (sleep-onset), and eszopiclone (longer duration). Panel B: Barbiturate versus benzodiazepine mechanism comparison showing barbiturates increasing chloride channel open duration (not frequency), ability to directly open channels at high doses (no ceiling effect), and resulting lethality in overdose. Panel C: Alternative sleep and anxiety agents showing ramelteon (melatonin agonist, no abuse), suvorexant (orexin antagonist, novel mechanism), buspirone (5-HT1A partial agonist, slow onset, no sedation or abuse), and gabapentinoids (calcium channel alpha-2-delta, anxiety and pain). Panel D: Alcohol pharmacology showing acute effects (GABA enhancement, NMDA inhibition), chronic neuroadaptation, withdrawal mechanism (GABA down, NMDA up, excitotoxicity), benzodiazepine cross-tolerance treatment, and pharmacotherapy for alcohol use disorder (disulfiram, naltrexone, acamprosate).</image>

III. Antidepressants

Antidepressant medications treat major depressive disorder and various anxiety disorders through modulation of monoamine neurotransmitter systems, primarily serotonin, norepinephrine, and to a lesser extent dopamine. The monoamine hypothesis of depression, though incomplete, posits that depression results from deficient monoamine neurotransmission, and antidepressants work by enhancing monoaminergic signaling. Current first-line agents include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which have largely replaced older tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) due to improved safety profiles. Despite their different mechanisms, all antidepressants share the characteristic of delayed therapeutic onset (2-4 weeks), which has led to theories about neuroplasticity and neurogenesis mediating their ultimate effects.

Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed antidepressant class, blocking the serotonin transporter (SERT) to increase synaptic serotonin concentrations. Available SSRIs include fluoxetine (long half-life, good for patients with compliance issues), sertraline (favorable side effect profile, commonly used), paroxetine (anticholinergic effects, discontinuation syndrome), escitalopram (active S-enantiomer of citalopram, clean pharmacology), and citalopram (QT prolongation at higher doses). Therapeutic effects require 2-4 weeks to emerge despite immediate transporter blockade, implicating downstream adaptations including receptor desensitization and altered gene expression. Common adverse effects include gastrointestinal disturbances (nausea, diarrhea), sexual dysfunction (decreased libido, anorgasmia), weight changes, and initial anxiety or insomnia. Serotonin syndrome, a potentially life-threatening hyperserotoninergic state, can occur when SSRIs are combined with other serotonergic drugs, particularly MAOIs; manifestations include altered mental status, autonomic instability, and neuromuscular abnormalities including tremor, hyperreflexia, and clonus.

Serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) both enhance serotonergic and noradrenergic transmission but differ significantly in safety profile. SNRIs including venlafaxine and duloxetine selectively block SERT and the norepinephrine transporter (NET) with minimal effects on other receptors, providing dual monoamine enhancement with a relatively clean side effect profile; they are particularly useful for patients with comorbid chronic pain conditions. TCAs (amitriptyline, nortriptyline, imipramine, desipramine) block serotonin and norepinephrine reuptake but also antagonize muscarinic, histamine H1, and alpha-1 adrenergic receptors, causing anticholinergic effects (dry mouth, constipation, urinary retention, cognitive impairment), sedation, orthostatic hypotension, and weight gain. Most concerning is TCA cardiotoxicity: sodium channel blockade produces QRS prolongation, and overdose can cause fatal arrhythmias; this narrow therapeutic index limits TCA use but they remain valuable for neuropathic pain, migraine prophylaxis, and treatment-resistant depression.

Monoamine oxidase inhibitors (MAOIs) were the first antidepressants discovered and remain effective for atypical and refractory depression but are rarely first-line due to drug and dietary interactions. These drugs inhibit monoamine oxidase enzymes (MAO-A and MAO-B) that degrade serotonin, norepinephrine, and dopamine, increasing levels of all three monoamines. Phenelzine and tranylcypromine are non-selective, irreversible inhibitors requiring new enzyme synthesis over 2-3 weeks for effects to resolve after discontinuation. The tyramine reaction (hypertensive crisis) occurs when patients on MAOIs consume tyramine-containing foods (aged cheeses, cured meats, fermented products) or sympathomimetic drugs; normally, intestinal and hepatic MAO metabolizes tyramine, but MAOI inhibition allows tyramine absorption to cause massive norepinephrine release. Serotonin syndrome risk is highest with MAOIs combined with other serotonergics, requiring a 2-week washout period between MAOIs and SSRIs (5 weeks for fluoxetine due to long half-life). Selegiline transdermal patch selectively inhibits MAO-B at low doses with reduced dietary restrictions, providing an option with improved safety.

<image>Panel A: Monoamine synapse diagram showing presynaptic neuron with serotonin and norepinephrine synthesis, vesicular storage, release, and reuptake transporters (SERT, NET), with SSRI and SNRI blocking reuptake to increase synaptic monoamines. Panel B: SSRI comparison showing fluoxetine (long half-life), sertraline (first-line), escitalopram (clean pharmacology), and common class effects (GI, sexual dysfunction, 2-4 week onset), with serotonin syndrome features and drug combinations to avoid. Panel C: TCA pharmacology showing multiple receptor effects (SERT/NET blockade, muscarinic antagonism, H1 antagonism, alpha-1 antagonism, sodium channel block), resulting adverse effects, and fatal overdose potential with QRS prolongation on ECG. Panel D: MAOI mechanism showing MAO-A and MAO-B inhibition increasing all three monoamines, tyramine reaction mechanism with foods (cheese, wine, cured meats), and serotonin syndrome risk requiring washout periods between serotonergic drugs.</image>

IV. Antipsychotics

Antipsychotic medications treat schizophrenia and other psychotic disorders primarily through dopamine D2 receptor antagonism, with newer agents adding serotonin 5-HT2A antagonism that modifies their clinical profile. These drugs effectively treat positive symptoms of psychosis (hallucinations, delusions, disorganized thought) but have limited efficacy for negative symptoms (anhedonia, social withdrawal, flat affect) and cognitive symptoms. First-generation (typical) antipsychotics differ from second-generation (atypical) agents primarily in their adverse effect profiles rather than efficacy for positive symptoms. Understanding the dopaminergic pathways in the brain helps explain both therapeutic effects and adverse effects of these medications.

First-generation antipsychotics exert their therapeutic effects through potent dopamine D2 receptor antagonism, with clinical efficacy correlating with D2 binding affinity. These drugs are classified by potency, which reflects D2 binding strength and predicts their side effect profile. High-potency agents like haloperidol and fluphenazine have strong D2 binding with relatively weak effects at muscarinic, histamine, and alpha-adrenergic receptors, resulting in a high incidence of extrapyramidal symptoms (EPS) but less sedation and anticholinergic effects. Low-potency agents like chlorpromazine have weaker D2 binding but greater antagonism at other receptor types, producing more sedation, orthostatic hypotension, and anticholinergic effects but fewer EPS. First-generation antipsychotics remain valuable due to their efficacy, availability in long-acting injectable (depot) formulations for patients with adherence difficulties, and lower cost, but their adverse effect burden limits use.

Extrapyramidal symptoms result from D2 blockade in the nigrostriatal pathway, disrupting the dopamine-acetylcholine balance essential for coordinated movement. These symptoms emerge in a characteristic temporal pattern corresponding to different pathophysiological mechanisms. Acute dystonia (sustained muscle contractions causing abnormal postures) develops within hours to days of antipsychotic initiation and responds rapidly to anticholinergic agents like benztropine. Akathisia (subjective and objective motor restlessness) emerges within days to weeks and is often treatment-limiting; management includes dose reduction, beta-blockers, or benzodiazepines. Drug-induced parkinsonism (rigidity, bradykinesia, tremor) develops over weeks and responds to anticholinergic agents or dose reduction. Tardive dyskinesia (involuntary choreiform movements, particularly of the face and tongue) develops after months to years of treatment, may be irreversible, and represents the most feared neurological complication; treatment includes discontinuation if possible, switching to clozapine, or vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine).

Second-generation (atypical) antipsychotics combine D2 antagonism with serotonin 5-HT2A antagonism, producing a different side effect profile with less EPS but significant metabolic effects. Clozapine is the most effective antipsychotic, particularly for treatment-resistant schizophrenia, but carries risks of agranulocytosis (requiring mandatory blood monitoring), myocarditis, seizures, and severe constipation. Olanzapine is highly effective but produces marked weight gain and metabolic syndrome (diabetes, dyslipidemia). Risperidone has the highest D2 affinity among atypicals, resulting in more EPS and prolactin elevation (causing gynecomastia, galactorrhea, amenorrhea) than other atypicals. Quetiapine has low D2 affinity and is more sedating, often used for insomnia and agitation as well as psychosis; it has fewer EPS but significant metabolic effects. Aripiprazole is unique as a D2 partial agonist (stabilizing dopamine signaling rather than blocking it), producing fewer metabolic effects and EPS but sometimes causing akathisia. The metabolic syndrome risk with atypical antipsychotics (particularly olanzapine and clozapine) requires baseline and ongoing monitoring of weight, glucose, and lipids.

<image>Panel A: Brain dopamine pathway diagram showing mesolimbic pathway (positive symptoms, therapeutic target), mesocortical pathway (negative/cognitive symptoms), nigrostriatal pathway (movement, EPS when blocked), and tuberoinfundibular pathway (prolactin regulation, hyperprolactinemia when blocked). Panel B: First-generation antipsychotic comparison showing high-potency agents (haloperidol, fluphenazine) with strong D2 binding, high EPS, less sedation versus low-potency agents (chlorpromazine) with weaker D2, more sedation, anticholinergic, and orthostatic hypotension. Panel C: EPS timeline showing acute dystonia (hours-days, responds to anticholinergics), akathisia (days-weeks, beta-blockers), parkinsonism (weeks, anticholinergics), and tardive dyskinesia (months-years, potentially irreversible, VMAT2 inhibitors). Panel D: Atypical antipsychotic profiles showing clozapine (most effective, agranulocytosis monitoring), olanzapine (high metabolic risk), risperidone (high D2, prolactin, EPS), quetiapine (sedating, low D2), and aripiprazole (partial D2 agonist, less metabolic effects, akathisia).</image>

V. Mood Stabilizers

Mood stabilizers form the cornerstone of bipolar disorder treatment, addressing both acute manic episodes and long-term prevention of mood cycling. Lithium, discovered over 70 years ago, remains the gold standard for bipolar disorder with the strongest evidence for preventing suicide, though its narrow therapeutic index requires careful monitoring. Anticonvulsants with mood-stabilizing properties provide alternatives and are often used in combination with lithium or atypical antipsychotics. Understanding the specific indications, monitoring requirements, and toxicities of each agent enables individualized treatment selection for this challenging chronic condition.

Lithium is a monovalent cation that remains the most effective mood stabilizer, with evidence for acute antimanic effects, prevention of both manic and depressive episodes, and unique anti-suicidal properties not demonstrated by other mood stabilizers. The mechanism of action is incompletely understood but involves multiple pathways including inhibition of inositol monophosphatase (depleting IP3 signaling substrates), inhibition of glycogen synthase kinase-3 (GSK-3, involved in neuronal plasticity), and effects on neurotrophic factors. The therapeutic range is narrow (0.6-1.2 mEq/L), and levels above 1.5 mEq/L produce toxicity. Lithium is entirely renally excreted and competes with sodium for reabsorption; factors reducing sodium (dehydration, low-sodium diet, diuretics, NSAIDs, ACE inhibitors) increase lithium reabsorption and risk toxicity. Required monitoring includes lithium levels (initially frequently, then every 3-6 months when stable), renal function (lithium causes chronic tubulointerstitial nephropathy and nephrogenic diabetes insipidus), and thyroid function (lithium inhibits thyroid hormone release, causing hypothyroidism in 20% of patients).

Lithium toxicity is a medical emergency with manifestations progressing from GI and neurological symptoms to life-threatening complications at higher levels. Mild toxicity (1.5-2.0 mEq/L) manifests as nausea, vomiting, diarrhea, and coarse tremor (distinguishable from the fine tremor seen at therapeutic levels). Moderate toxicity (2.0-2.5 mEq/L) produces ataxia, hyperreflexia, confusion, and dysarthria. Severe toxicity (greater than 2.5 mEq/L) can cause seizures, coma, cardiac arrhythmias, and death. Treatment of lithium toxicity involves immediate discontinuation of lithium, intravenous fluid resuscitation (normal saline) to enhance renal excretion, and hemodialysis for severe toxicity or renal impairment. Factors precipitating toxicity include volume depletion (vomiting, diarrhea, fever), renal impairment, drug interactions (especially NSAIDs, ACE inhibitors, thiazide diuretics), and intentional overdose. Patients should be educated about maintaining hydration, avoiding NSAIDs, and recognizing early toxicity symptoms.

Several anticonvulsants have mood-stabilizing properties and are used as alternatives or adjuncts to lithium. Valproate (valproic acid, divalproex) is effective for acute mania and maintenance therapy, particularly for rapid-cycling and mixed episodes; adverse effects include hepatotoxicity (requiring baseline and periodic liver function monitoring), teratogenicity (neural tube defects, contraindicated in pregnancy), thrombocytopenia, and weight gain. Carbamazepine is effective for acute mania but limited by numerous drug interactions through CYP450 induction and risks of aplastic anemia and Stevens-Johnson syndrome; it also causes SIADH with resulting hyponatremia. Lamotrigine is uniquely effective for bipolar depression (not acute mania) and maintenance, with the major concern being Stevens-Johnson syndrome and toxic epidermal necrolysis requiring very slow dose titration over 8 weeks. Atypical antipsychotics (quetiapine, olanzapine, aripiprazole) are often combined with mood stabilizers and have indications for acute mania and maintenance; quetiapine and the olanzapine-fluoxetine combination are FDA-approved for bipolar depression.

<image>Panel A: Lithium mechanism and effects showing multiple proposed mechanisms (inositol depletion, GSK-3 inhibition), antimanic, prophylactic, and anti-suicidal effects, renal excretion with sodium competition, and narrow therapeutic window (0.6-1.2 mEq/L). Panel B: Lithium monitoring requirements showing serum levels, renal function (nephrogenic DI, interstitial nephritis), thyroid function (hypothyroidism), and drug interactions that increase levels (NSAIDs, ACE inhibitors, thiazide diuretics, dehydration). Panel C: Lithium toxicity spectrum showing mild (1.5-2.0 mEq/L, GI, tremor), moderate (2.0-2.5 mEq/L, ataxia, hyperreflexia), and severe (>2.5 mEq/L, seizures, coma), with treatment algorithm including discontinuation, IV fluids, and dialysis indications. Panel D: Anticonvulsant mood stabilizers showing valproate (mania and maintenance, hepatotoxic, teratogenic), carbamazepine (mania, drug interactions, hyponatremia), and lamotrigine (bipolar depression, SJS requiring slow titration), with atypical antipsychotic adjuncts listed.</image>

VI. Drugs for Neurodegenerative Diseases

Parkinson disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra, resulting in the classic motor features of bradykinesia, rigidity, resting tremor, and postural instability. Pharmacotherapy aims to restore dopaminergic transmission through multiple mechanisms, with levodopa remaining the most effective treatment for motor symptoms. The progressive nature of the disease and the development of motor complications with long-term levodopa therapy create challenges in optimizing treatment over time. Non-dopaminergic therapies address specific symptoms and may provide neuroprotective effects, though disease-modifying treatments remain elusive.

Levodopa, the metabolic precursor of dopamine, remains the gold standard for treating Parkinson disease motor symptoms and is administered with carbidopa to prevent peripheral conversion to dopamine. Dopamine itself cannot cross the blood-brain barrier, but levodopa crosses and is converted to dopamine by aromatic L-amino acid decarboxylase in the brain. Carbidopa inhibits peripheral decarboxylase, reducing conversion of levodopa to dopamine outside the CNS, which decreases peripheral side effects (nausea, orthostatic hypotension) and increases central bioavailability. Initial response to levodopa is typically excellent (the "honeymoon period"), but long-term treatment produces motor complications including wearing-off (decreased duration of benefit between doses) and dyskinesias (involuntary choreiform movements at peak effect). Strategies to minimize complications include delayed initiation in younger patients, using the lowest effective dose, and combination with other dopaminergic agents. Entacapone, a catechol-O-methyltransferase (COMT) inhibitor, blocks peripheral levodopa metabolism, extending its duration of action.

Dopamine agonists (pramipexole, ropinirole, rotigotine) directly stimulate D2 and D3 receptors, providing symptomatic benefit as monotherapy in early disease or as adjuncts to levodopa in advanced disease. These agents produce fewer motor complications than levodopa but are less effective for motor symptoms and cause more psychiatric adverse effects (hallucinations, impulse control disorders including pathological gambling and hypersexuality). MAO-B inhibitors (selegiline, rasagiline) reduce dopamine breakdown in the brain, providing mild symptomatic benefit and possible neuroprotective effects; they can be used as monotherapy in early disease or as levodopa adjuncts. Amantadine has multiple mechanisms including NMDA antagonism and enhancement of dopamine release; it provides modest symptomatic benefit and uniquely reduces levodopa-induced dyskinesias. Anticholinergics (benztropine, trihexyphenidyl) address the dopamine-acetylcholine imbalance in the basal ganglia, helping tremor but limited by cognitive adverse effects, particularly in elderly patients.

Alzheimer disease drugs provide modest symptomatic benefit without altering disease progression, targeting the cholinergic deficit that results from degeneration of basal forebrain cholinergic neurons. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase acetylcholine availability by blocking its breakdown, producing modest improvements in cognition, function, and behavior in mild to moderate disease. Donepezil is the most commonly prescribed, with once-daily dosing and primarily hepatic metabolism. Rivastigmine is available as a transdermal patch, reducing GI side effects. Galantamine additionally acts as an allosteric modulator of nicotinic receptors. Memantine is an NMDA receptor antagonist that blocks excessive glutamate signaling implicated in excitotoxic neuronal damage; it is approved for moderate to severe Alzheimer disease and may be combined with cholinesterase inhibitors. Newer agents targeting amyloid pathology (aducanumab, lecanemab) have received FDA approval but remain controversial due to modest efficacy, significant adverse effects (amyloid-related imaging abnormalities), and high cost.

<image>Panel A: Parkinson disease pathophysiology showing dopaminergic neuron loss in substantia nigra, resulting dopamine deficiency in striatum, and treatment targets: levodopa (dopamine precursor), dopamine agonists (D2/D3), MAO-B inhibitors (decreased breakdown), COMT inhibitors (extended levodopa), and anticholinergics (balance restoration). Panel B: Levodopa pharmacokinetics showing oral absorption, carbidopa blocking peripheral conversion (reducing nausea and hypotension), CNS entry and conversion to dopamine, honeymoon period, and late complications (wearing-off, dyskinesias). Panel C: Alzheimer disease treatments showing cholinergic hypothesis with basal forebrain degeneration, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increasing ACh, memantine blocking NMDA excitotoxicity, and newer anti-amyloid antibodies (controversial). Panel D: Comparison of neurodegenerative disease treatments showing Parkinson (multiple dopaminergic strategies, motor benefit), Alzheimer (modest symptomatic benefit, no disease modification), MS (numerous disease-modifying therapies), and ALS (riluzole, edaravone with minimal benefit).</image>

VII. Antiepileptic Drugs

Antiepileptic drugs (AEDs) prevent seizures by modulating neuronal excitability through several mechanisms including sodium channel blockade, calcium channel modulation, and enhancement of GABAergic inhibition. Drug selection depends on seizure type, with some agents having broad-spectrum efficacy across multiple seizure types while others are specific to particular seizure types. The goal of therapy is seizure freedom with minimal adverse effects, achieved in approximately 70% of patients with monotherapy or combination therapy. Understanding mechanisms helps predict efficacy for specific seizure types and anticipate drug interactions and adverse effects.

Traditional antiepileptic drugs established the mechanistic foundations for seizure control and remain widely used. Phenytoin blocks voltage-gated sodium channels in a use-dependent manner, stabilizing the inactivated state and reducing sustained high-frequency neuronal firing; it is effective for focal and generalized tonic-clonic seizures with a narrow therapeutic index and numerous drug interactions through CYP450 induction. Carbamazepine shares the sodium channel mechanism with phenytoin and is effective for focal seizures and trigeminal neuralgia; it induces its own metabolism (autoinduction) and other CYP450 substrates. Valproate has multiple mechanisms including sodium channel blockade, T-type calcium channel inhibition, and enhanced GABA, providing broad-spectrum efficacy for focal and generalized seizures; it is first-line for generalized epilepsies but teratogenic and hepatotoxic. Phenobarbital enhances GABA-A receptor function, used for generalized seizures and status epilepticus, limited by sedation and dependence. Ethosuximide specifically blocks T-type calcium channels in thalamic neurons responsible for the spike-wave discharges of absence seizures; it is first-line for childhood absence epilepsy but ineffective for other seizure types.

Newer antiepileptic drugs generally offer improved tolerability and fewer drug interactions compared to traditional agents. Lamotrigine blocks sodium channels and is effective for focal and generalized seizures, including absence and myoclonic; it is first-line for many epilepsy types, particularly useful in women of childbearing potential due to better teratogenicity profile than valproate, but requires very slow titration due to serious rash risk (Stevens-Johnson syndrome). Levetiracetam binds to synaptic vesicle protein SV2A by an incompletely understood mechanism; it has broad-spectrum efficacy with minimal drug interactions and no hepatic metabolism, though psychiatric adverse effects (irritability, depression) may limit use. Topiramate has multiple mechanisms (sodium channels, GABA enhancement, glutamate inhibition, carbonic anhydrase inhibition); it is effective for focal and generalized seizures and has additional indications for migraine prophylaxis, but causes cognitive impairment, kidney stones, and weight loss. Gabapentin and pregabalin bind to alpha-2-delta subunits of voltage-gated calcium channels; they are used for focal seizures and extensively for neuropathic pain and anxiety, with relatively few drug interactions.

Seizure type guides antiepileptic drug selection, as some drugs are effective for specific seizure types while others may worsen certain seizures. Focal (partial) seizures, whether simple, complex, or secondarily generalized, respond to sodium channel blockers (carbamazepine, phenytoin, lamotrigine, lacosamide) and broad-spectrum agents (valproate, levetiracetam). Generalized tonic-clonic seizures respond to valproate, lamotrigine, levetiracetam, and topiramate; phenytoin and carbamazepine are also effective but may worsen absence or myoclonic seizures if misdiagnosed. Absence seizures require ethosuximide or valproate; sodium channel blockers are ineffective and may worsen absence seizures. Myoclonic seizures respond to valproate and levetiracetam; sodium channel blockers may worsen myoclonic seizures. Status epilepticus requires rapid-acting agents with the first-line being benzodiazepines (lorazepam IV), followed by phenytoin or fosphenytoin loading, and phenobarbital or levetiracetam for refractory cases; propofol or pentobarbital may be needed for super-refractory status.

<image>Panel A: Antiepileptic drug mechanisms showing sodium channel blockers (phenytoin, carbamazepine, lamotrigine) reducing action potential firing, T-type calcium channel blockers (ethosuximide) for thalamic pacemaker in absence, GABA enhancers (phenobarbital, benzodiazepines) increasing inhibition, and SV2A binding (levetiracetam). Panel B: Traditional AED comparison showing phenytoin (sodium channel, focal/GTC, narrow index, gingival hyperplasia), carbamazepine (sodium channel, focal, SIADH, SJS), valproate (broad mechanism, broad spectrum, teratogenic, hepatotoxic), and ethosuximide (T-type calcium, absence only). Panel C: Newer AED comparison showing lamotrigine (sodium channel, broad spectrum, slow titration for SJS), levetiracetam (SV2A, broad spectrum, psychiatric effects), topiramate (multiple mechanisms, cognitive effects, weight loss), and gabapentinoids (calcium channel alpha-2-delta, focal and pain). Panel D: Seizure type-drug selection matrix showing focal (carbamazepine, lamotrigine, levetiracetam), GTC (valproate, lamotrigine, levetiracetam), absence (ethosuximide, valproate), myoclonic (valproate, levetiracetam), and status epilepticus (lorazepam, phenytoin, phenobarbital).</image>

VIII. Opioid Pharmacology

Opioid analgesics represent the most effective drugs for moderate to severe pain, acting through specific opioid receptors in the central and peripheral nervous system to produce analgesia along with numerous other effects. Three major opioid receptor types mediate distinct effects: mu (analgesia, euphoria, respiratory depression, constipation), kappa (analgesia, dysphoria, sedation), and delta (analgesia, mood modulation). The mu receptor is the primary target for clinically used opioid analgesics, with full agonists producing the greatest analgesia but also the greatest risk of adverse effects and dependence. Understanding receptor pharmacology enables rational selection among opioids and explains the utility of partial agonists and antagonists.

Full opioid agonists produce maximal mu receptor activation and include the most potent analgesics available. Morphine remains the standard against which other opioids are compared, with moderate oral bioavailability, active glucuronide metabolites (morphine-6-glucuronide is analgesic; morphine-3-glucuronide may cause neuroexcitation), and renal excretion of metabolites requiring caution in kidney disease. Hydromorphone is more potent than morphine with possibly fewer metabolite-related issues. Fentanyl is extremely potent (approximately 100 times morphine) and highly lipophilic, enabling transdermal and transmucosal delivery; its rapid onset makes it popular for procedural analgesia and breakthrough cancer pain but also increases abuse potential. Methadone has a very long and variable half-life (8-59 hours) complicating dosing, QT prolongation risk, and unique NMDA receptor antagonism that may benefit neuropathic pain and prevent tolerance; it is also used for opioid use disorder treatment. Oxycodone and hydrocodone are commonly prescribed oral opioids with higher oral bioavailability than morphine, frequently formulated in combination products with acetaminophen.

Partial agonists and mixed agonist-antagonists provide alternatives with different risk-benefit profiles. Buprenorphine is a partial mu agonist with high receptor affinity, producing a ceiling effect on analgesia and respiratory depression that improves safety; it is used for pain management (transdermal, buccal, sublingual) and, importantly, for opioid use disorder treatment. The ceiling effect means that buprenorphine can precipitate withdrawal if given to patients on full agonists by displacing the full agonist and providing less mu activation. Tramadol is a weak mu agonist with additional serotonin and norepinephrine reuptake inhibition, useful for moderate pain but with seizure risk and serotonin syndrome potential. Mixed agonist-antagonists (nalbuphine, pentazocine, butorphanol) are kappa agonists with mu antagonist or partial agonist activity; they provide analgesia with a ceiling on respiratory depression but can precipitate withdrawal in opioid-dependent patients and cause dysphoria.

Opioid antagonists competitively block opioid receptors and are critical for overdose reversal and addiction treatment. Naloxone is the primary agent for opioid overdose reversal, rapidly displacing opioid agonists from receptors; it can be administered intravenously, intramuscularly, subcutaneously, or intranasally. Naloxone has a shorter half-life than most opioids (30-90 minutes versus hours for methadone), requiring repeated dosing or continuous infusion to prevent re-sedation. Administration of naloxone to opioid-dependent individuals precipitates acute withdrawal, which is extremely unpleasant but not life-threatening; the dose should be titrated to restore adequate respiration while minimizing withdrawal severity when possible. Naltrexone is an oral opioid antagonist with a longer duration of action, used for relapse prevention in opioid and alcohol use disorders; it is also available as a monthly intramuscular injection (extended-release naltrexone). Methylnaltrexone, naloxegol, and naldemedine are peripherally-restricted opioid antagonists that do not cross the blood-brain barrier, used specifically for opioid-induced constipation without affecting central analgesia.

<image>Panel A: Opioid receptor types showing mu (analgesia, euphoria, respiratory depression, constipation, miosis, dependence), kappa (analgesia, dysphoria, sedation), and delta (analgesia, mood) receptors, with clinical opioids primarily targeting mu receptor. Panel B: Full opioid agonist comparison showing morphine (standard, active metabolites, renal clearance), fentanyl (very potent, lipophilic, transdermal), methadone (long half-life, QT, NMDA antagonism), and oral opioids (oxycodone, hydrocodone with higher bioavailability). Panel C: Partial agonist and antagonist spectrum showing buprenorphine (partial mu agonist, ceiling effect, addiction treatment), tramadol (weak mu plus SNRI, seizure risk), and mixed agonist-antagonists (kappa agonist/mu antagonist, can precipitate withdrawal). Panel D: Opioid antagonist comparison showing naloxone (IV/IM/SC/IN, rapid reversal, short half-life requiring repeat dosing, precipitates withdrawal), naltrexone (oral or monthly IM, addiction treatment), and peripheral antagonists (methylnaltrexone, naloxegol for constipation without crossing BBB).</image>

IX. Opioid Use and Misuse

Opioid effects extend beyond analgesia to multiple organ systems, with both therapeutic and adverse consequences. Analgesia results from mu receptor activation in the spinal cord dorsal horn, brainstem, and higher cortical areas, modifying both the sensory and affective components of pain. Euphoria results from increased dopamine release in mesolimbic reward pathways, contributing to abuse potential. Respiratory depression occurs through mu receptor-mediated reduction in brainstem sensitivity to carbon dioxide, representing the principal cause of death in opioid overdose. Constipation results from mu receptor activation in the enteric nervous system, reducing motility and increasing sphincter tone; unlike most opioid effects, tolerance to constipation does not develop. Miosis (pupillary constriction) provides a useful clinical sign of opioid effect. Pruritus may result from histamine release or central mu receptor effects and is common with spinal opioid administration.

The distinction between tolerance, physical dependence, and addiction is fundamental to understanding opioid therapy and misuse. Tolerance is a pharmacological phenomenon in which repeated exposure reduces drug effect, requiring dose escalation to maintain the same response; tolerance develops at different rates for different effects (rapidly for euphoria and nausea, slowly for constipation, variably for analgesia). Physical dependence is a physiological state in which abrupt discontinuation produces withdrawal syndrome; it is an expected consequence of chronic opioid therapy and does not indicate addiction. Withdrawal symptoms are essentially opposite to opioid effects: mydriasis, lacrimation, rhinorrhea, piloerection, diarrhea, anxiety, insomnia, muscle aches, and drug craving; while extremely unpleasant, opioid withdrawal is not life-threatening (unlike alcohol or benzodiazepine withdrawal). Addiction (opioid use disorder) is a behavioral syndrome characterized by compulsive use despite harm, loss of control, and psychological preoccupation; it involves reward circuitry changes beyond simple physical dependence.

Opioid overdose is a medical emergency characterized by the triad of decreased level of consciousness, respiratory depression, and miosis. Management follows standard resuscitation principles with naloxone as the specific antidote. Airway protection and assisted ventilation are critical, as death results from respiratory failure. Naloxone dosing begins at 0.4-2 mg intravenously (or intramuscularly/subcutaneously/intranasally if IV access unavailable), repeated every 2-3 minutes until respiratory rate and consciousness improve. The goal is to restore adequate ventilation, not necessarily full arousal, which would precipitate severe withdrawal in dependent individuals. Re-sedation may occur when naloxone's effect wanes (30-90 minutes) while the opioid is still present; monitoring should continue and repeat naloxone doses or continuous infusion may be needed, particularly for long-acting opioids like methadone. Patients with suspected overdose should be monitored for several hours even after apparent recovery.

Medication-assisted treatment (MAT) for opioid use disorder employs pharmacological agents to reduce craving, prevent withdrawal, and block euphoric effects, dramatically improving outcomes compared to abstinence-only approaches. Methadone, a full mu agonist, is administered once daily through licensed clinics, preventing withdrawal and reducing craving while blocking euphoria from illicit opioids through cross-tolerance; its long half-life provides stable blood levels. Buprenorphine, a partial mu agonist, is available for office-based treatment following specific prescriber certification; its ceiling effect provides safety advantages, and the buprenorphine/naloxone combination product (Suboxone) discourages injection misuse. Naltrexone, a mu antagonist, blocks opioid effects and is available as daily oral or monthly injectable (extended-release) formulations; it requires complete opioid abstinence before initiation to avoid precipitating withdrawal and works best in highly motivated patients. Evidence strongly supports MAT, particularly methadone and buprenorphine, for reducing mortality, HIV transmission, and criminal activity while improving treatment retention and quality of life.

<image>Panel A: Opioid effects by organ system showing CNS (analgesia, euphoria, sedation, respiratory depression), eye (miosis), GI (constipation, nausea), skin (pruritus, histamine release), and cardiovascular (bradycardia, hypotension), with indication of which effects develop tolerance. Panel B: Tolerance, dependence, and addiction distinctions showing tolerance (pharmacological adaptation, dose escalation needed), physical dependence (physiological state, withdrawal on cessation, expected with chronic use), and addiction (behavioral disorder, compulsive use despite harm, involves reward circuitry changes). Panel C: Opioid overdose triad showing decreased consciousness, respiratory depression, and miosis, with management algorithm: airway protection, assisted ventilation, naloxone 0.4-2 mg repeated as needed, monitoring for re-sedation, and consideration of infusion for long-acting opioids. Panel D: Medication-assisted treatment comparison showing methadone (full agonist, clinic-based, once daily, stable), buprenorphine (partial agonist, office-based, ceiling effect safety), and naltrexone (antagonist, requires abstinence first, blocks opioid effects), with evidence for mortality reduction.</image>

X. Non-Opioid Analgesics

Acetaminophen (paracetamol) is one of the most widely used analgesics and antipyretics worldwide, with a mechanism distinct from NSAIDs and opioids that remains incompletely understood. The drug inhibits cyclooxygenase centrally (and weakly peripherally), possibly through a COX-3 variant or peroxide-dependent inhibition, reducing prostaglandin synthesis in the CNS. Acetaminophen provides effective analgesia for mild to moderate pain and reduces fever but lacks the anti-inflammatory effects of NSAIDs and the efficacy of opioids for severe pain. The maximum daily dose is 3-4 grams (lower in patients with liver disease or chronic alcohol use), with hepatotoxicity being the major safety concern. Toxicity occurs through formation of the reactive metabolite NAPQI, normally detoxified by glutathione conjugation; in overdose, glutathione depletion allows NAPQI accumulation and hepatocyte damage. N-acetylcysteine (NAC) is the antidote, providing cysteine for glutathione synthesis; it is most effective when given within 8 hours of ingestion but provides benefit even later.

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase enzymes (COX-1 and COX-2) that catalyze prostaglandin synthesis, producing analgesic, antipyretic, and anti-inflammatory effects but also causing characteristic adverse effects. COX-1 is constitutively expressed and generates prostaglandins that protect gastric mucosa, maintain renal perfusion, and support platelet function. COX-2 is induced by inflammation and produces prostaglandins mediating pain and fever. Non-selective NSAIDs (ibuprofen, naproxen, ketorolac) inhibit both isoforms, providing anti-inflammatory effects but causing GI toxicity (ulceration, bleeding) through COX-1 inhibition; naproxen has the most favorable cardiovascular safety profile among non-selective NSAIDs. COX-2 selective inhibitors (celecoxib) spare COX-1 and reduce GI toxicity but increase cardiovascular risk (myocardial infarction, stroke) through unopposed thromboxane-mediated platelet aggregation. All NSAIDs cause renal effects including acute kidney injury (particularly in volume-depleted patients), sodium retention, and hypertension through inhibition of renal prostaglandins that maintain glomerular filtration and natriuresis.

Adjuvant analgesics are drugs with primary indications other than pain that provide analgesia for specific pain types, particularly neuropathic pain that responds poorly to conventional analgesics. Antidepressants, particularly SNRIs (duloxetine, venlafaxine) and TCAs (amitriptyline, nortriptyline), are first-line for neuropathic pain, with duloxetine FDA-approved for diabetic neuropathy and fibromyalgia; their analgesic effect occurs at lower doses and with faster onset than antidepressant effects. Anticonvulsants gabapentin and pregabalin are first-line for neuropathic pain, binding to alpha-2-delta calcium channel subunits to reduce excitatory neurotransmitter release; they are particularly useful for postherpetic neuralgia and diabetic neuropathy. Carbamazepine is specifically effective for trigeminal neuralgia. Topical agents include lidocaine patches (local anesthetic effect) and capsaicin (depletes substance P from sensory neurons); they are useful for localized neuropathic pain with minimal systemic effects. Muscle relaxants (cyclobenzaprine, methocarbamol) are used for acute musculoskeletal pain with muscle spasm, though evidence for efficacy is limited and sedation is common.

The WHO analgesic ladder provides a framework for pain management, with non-opioid analgesics forming the foundation for mild pain, weak opioids added for moderate pain, and strong opioids for severe pain, with adjuvants used at all levels as indicated. For mild pain, acetaminophen or NSAIDs are used alone or in combination, with selection based on inflammation presence and patient risk factors. For moderate pain, tramadol or combination products (oxycodone/acetaminophen, hydrocodone/acetaminophen) are added. For severe pain, strong opioids (morphine, hydromorphone, fentanyl, oxycodone) are used, often maintaining non-opioid analgesics for their opioid-sparing effect. Adjuvant analgesics are incorporated based on pain type: antidepressants and anticonvulsants for neuropathic pain, corticosteroids for inflammatory or compression pain, bisphosphonates or denosumab for bone pain. Multimodal analgesia, combining agents with different mechanisms, provides superior pain control with reduced adverse effects compared to single-agent therapy, reflecting current best practices.

<image>Panel A: Acetaminophen pharmacology showing central COX inhibition mechanism, analgesic and antipyretic effects without anti-inflammatory action, maximum dosing (3-4 g/day), hepatotoxic metabolite NAPQI formation when glutathione depleted, and N-acetylcysteine antidote mechanism. Panel B: NSAID mechanism comparison showing COX-1 (constitutive, GI protection, renal perfusion, platelets) and COX-2 (inducible, inflammation), non-selective NSAIDs (GI and renal toxicity), and COX-2 selective agents (less GI toxicity, more CV risk). Panel C: Adjuvant analgesic comparison for neuropathic pain showing antidepressants (duloxetine, TCAs, first-line), anticonvulsants (gabapentin, pregabalin, first-line), carbamazepine (trigeminal neuralgia), and topicals (lidocaine, capsaicin for localized pain). Panel D: WHO analgesic ladder showing Step 1 (non-opioids for mild pain), Step 2 (weak opioids added for moderate pain), Step 3 (strong opioids for severe pain), with adjuvants at all levels and multimodal analgesia principles.</image>

Summary

• Benzodiazepines potentiate GABA-A receptor function by increasing chloride channel opening frequency, producing anxiolytic, sedative, muscle relaxant, and anticonvulsant effects; flumazenil reverses benzodiazepine effects but may precipitate seizures
• Z-drugs (zolpidem, zaleplon, eszopiclone) selectively bind alpha-1-containing GABA-A receptors for sedation with theoretically reduced anxiolytic effects
• SSRIs are first-line antidepressants, blocking serotonin reuptake with 2-4 week onset; serotonin syndrome occurs with serotonergic drug combinations, particularly MAOIs
• TCAs block monoamine reuptake plus multiple receptors, causing anticholinergic, cardiac, and sedative adverse effects; cardiotoxic in overdose
• First-generation antipsychotics cause extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism, tardive dyskinesia) through nigrostriatal D2 blockade
• Atypical antipsychotics combine D2 and 5-HT2A blockade with less EPS but metabolic syndrome risk; clozapine is most effective but requires monitoring for agranulocytosis
• Lithium treats bipolar disorder with narrow therapeutic index; monitor levels, renal function, and thyroid; toxicity causes neurological deterioration
• Parkinson disease treatment targets dopamine restoration: levodopa/carbidopa (most effective), dopamine agonists, MAO-B inhibitors, COMT inhibitors
• Antiepileptic drugs target sodium channels (phenytoin, carbamazepine, lamotrigine), GABA (phenobarbital, benzodiazepines), or T-type calcium (ethosuximide for absence); drug selection matches seizure type
• Opioids produce analgesia, euphoria, respiratory depression, and constipation through mu receptors; naloxone reverses overdose; medication-assisted treatment (methadone, buprenorphine, naltrexone) improves outcomes in opioid use disorder

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown